658
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis

, PharmD, PhD, , MD, , PharmD, , PharmD, , , MA & , MPH, PhD show all

References

  • Chen LH, Hedegaard H, Warner M. QuickStats: rates of deaths from drug poisoning and drug poisoning involving opioid analgesics—United States, 1999–2013. MMWR Morb Mortal Wkly Rep. 2015;64:32.
  • Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452.
  • Hughes A, Williams MR, Lipari RN, Bose J, Copello EA, Kroutil LA. Prescription Drug Use and Misuse in the United States: Results From the 2015 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.
  • IMS Institute. Medicines Use and Spending in the U.S. A Review of 2015 and Outlook to 2020. Parsippany, NJ: IMS Institute for Healthcare Informatics; 2016.
  • Volkow ND. America's Addiction To Opioids: Heroin and Prescription Drug Abuse. Senate Caucus on International Narcotics Control. Rockville, MD: National Institute on Drug Abuse; 2014.
  • Office of National Drug Control Policy. Epidemic: Responding to America's Prescription Drug Abuse Crisis. Washington, DC: Office of National Drug Control Policy, The White House; 2011.
  • Tennessee Department of Health. Tennessee Chronic Pain Guidelines: Clinical Practice Guidelines for Outpatient Management of Chronic Non-Malignant Pain. Nashville, TN: Tennessee Department of Health; 2014.
  • Office of National Drug Control Policy. National Drug Control Strategy—2016. Washington, DC: Office of National Drug Control Policy, The White House; 2016.
  • Snyder ME, Zillich AJ, Primack BA, et al. Exploring successful community pharmacist-physician collaborative working relationships using mixed methods. Res Soc Admin Pharm. 2010;6:307–323.
  • Chui MA, Stone JA, Odukoya OK, Maxwell L. Facilitating collaboration between pharmacists and physicians using an iterative interview process. J Am Pharm Assoc. 2014;54:35–41.
  • Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander G. Prescription drug abuse: a national survey of primary care physicians. JAMA Intern Med. 2015;175:302–304.
  • Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. Primary care physicians' knowledge and attitudes regarding prescription opioid abuse and diversion. Clin J Pain. 2015;32:279–284.
  • Hagemeier NE, Murawski MM, Lopez NC, Alamian A, Pack RP. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication. Res Soc Admin Pharm. 2014;10:562–575.
  • Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;248:761–768.
  • Bhamb B, Brown D, Hariharan J, Anderson J, Balousek S, Fleming MF. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22:1859–1865.
  • Wright RE, Reed N, Carnes N, Kooreman HE. Concern about the expanding prescription drug epidemic: a survey of licensed prescribers and dispensers. Pain Physician. 2016;19:E197–E208.
  • Jamison RN, Sheehan KA, Scanlan E, Matthews M, Ross EL. Beliefs and attitudes about opioid prescribing and chronic pain management: survey of primary care providers. J Opioid Manag. 2014;10:375–382.
  • Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013;22:574–580.
  • Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff (Millwood). 2015;34:484–492.
  • Cochran G, Field C, Lawson K, Erickson C. Pharmacists' knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. J Pharm Health Serv Res. 2013;4:71–79.
  • Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28:404–412.
  • Fleming ML, Barner JC, Brown CM, Shepherd MD, Strassels SA, Novak S. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions. J Am Pharm Assoc. 2014;54:241–250.
  • AMA House of Delegates. AMA meeting: pharmacists warned on intruding into prescribing decisions. http://www.amednews.com/article/20130701/house/130709956/7/. Published 2013. Accessed September 15, 2016.
  • National Association of Boards of Pharmacy. Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances. Chicago, IL: National Association of Boards of Pharmacy; 2015.
  • Paulozzi LJ, Mack KA, Hockenberry JM. Vital Signs: Variation among states in prescribing of opioid pain relievers and benzodiazepines—United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63:563–568.
  • Hagemeier NE, Tudiver F, Brewster S, Hagy EJ, Hagaman A, Pack RP. Prescription drug abuse communication: a qualitative analysis of prescriber and pharmacist perceptions and behaviors. Res Soc Admin Pharm. 2016;12:937–948.
  • Morgan DL. Focus Groups as Qualitative Research. Newbury Park, CA: Sage Publications; 1988.
  • Morgan DL. Successful Focus Groups: Advancing the State of the Art. Newbury Park, CA: Sage Publications; 1993.
  • Gilchrist VJ, Williams RL. Key informant interviews. In: Crabtree BF, Miller WL, eds. Doing Qualitative Research. Newbury Park, CA: Sage Publications; 1999:71–88.
  • Tong A, Sainsbury P, Craig J. Consolidated Criteria for Reporting Qualitative Research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349–357.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.